Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,449 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Parkinsonism Clear all
Completed Phase 2 Interventional Results available

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

NCT04932434
View directory record Official record
Conditions
Parkinson Disease, Depression, Anxiety
Interventions
Psilocybin therapy
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444

NCT05009199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[18F]MNI-444
Drug
Lead sponsor
Invicro
Other
Eligibility
30 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Phase 3 Interventional

Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease

NCT00058838
View directory record Official record
Conditions
Parkinson Disease
Interventions
sumanirole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2006 · Synced Oct 21, 2026, 7:22 AM EDT
Not listed Not applicable Interventional

Serious Games for Parkinson's Disease

NCT05551338
View directory record Official record
Conditions
Parkinson Disease, Parkinson
Interventions
Serious games
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 21, 2026, 7:22 AM EDT
Terminated Phase 1 Interventional

A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease

NCT01803945
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AVE8112, Placebo
Drug
Lead sponsor
Michael J. Fox Foundation for Parkinson's Research
Other
Eligibility
35 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 21, 2026, 7:22 AM EDT
Terminated Not applicable Interventional

Temporally Optimized Patterned Stimulation (TOPS®) Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease

NCT04390867
View directory record Official record
Conditions
Parkinson Disease
Interventions
TOPS1 DBS, TOPS2 DBS, TOPS3 DBS, Standard DBS
Device
Lead sponsor
Deep Brain Innovations LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Gainesville, Florida • Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intelligibility Assessment for Parkinson's Disease

NCT04829006
View directory record Official record
Conditions
Parkinson Disease
Interventions
Understand Me For Life
Device
Lead sponsor
Long Island University
Other
Eligibility
30 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact

NCT02236286
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Exercise
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

NCT00407095
View directory record Official record
Conditions
Advanced Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Oct 21, 2026, 7:22 AM EDT
Enrolling by invitation Not applicable Interventional

Vibrotactile Coordinated Reset for the Treatment of Advanced Parkinson's Disease

NCT05504902
View directory record Official record
Conditions
Parkinson Disease
Interventions
Vibrotactile coordinated reset
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 21, 2026, 7:22 AM EDT
Recruiting Not applicable Interventional

A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson Disease

NCT07705373
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
MR-005 (MedRhythms, Inc., Portland, ME)
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 7:22 AM EDT
Completed No phase listed Observational

PET Scanning in Parkinson s Disease

NCT00024622
View directory record Official record
Conditions
Schizophrenia, Parkinson's Disease
Interventions
O-15 Water, 18F-Fluoro-L-dopa
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

NCT05318937
View directory record Official record
Conditions
Parkinson Disease, Cognitive Dysfunction
Interventions
SAGE-718-matching placebo, SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 21, 2026, 7:22 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Neuroimaging of Parkinson's

NCT07024875
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 21, 2026, 7:22 AM EDT
Not yet recruiting Not applicable Interventional

Automated Image-Guided Programming of Deep Brain Stimulation (DBS) for Parkinson's Disease

NCT07215481
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Shame Control (Baseline), Standard of Care Deep Brain Stimulation, Illumina 3D Deep Brain Stimulation, Illumina 3D Deep Brain Stimulation Reduced Amplitude, Illumina 3D Deep Brain Stimulation Higher Amplitude
Device
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management

NCT03103919
View directory record Official record
Conditions
Parkinson´s Disease
Interventions
Kinesia-ONE™, Kinesia-360™, Rotigotine
Device · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Winfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

NCT01711866
View directory record Official record
Conditions
Advanced Idiopathic Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
30 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anniston, Alabama • Atlantis, Florida • Miami Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 21, 2026, 7:22 AM EDT
Withdrawn Phase 2 Interventional

Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)

NCT01565395
View directory record Official record
Conditions
Parkinson Disease, Amyotrophic Lateral Sclerosis
Interventions
Incobotulinum Toxin A, placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Phase 2 Interventional

ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease

NCT01336088
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ADX48621, Placebo
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 21, 2026, 7:22 AM EDT
Recruiting Phase 2 Interventional

A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations

NCT07514858
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Lu AF28996, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
40 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Farmington Hills, Michigan • Round Rock, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 21, 2026, 7:22 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

NCT03457493
View directory record Official record
Conditions
Parkinson Disease
Interventions
DPA-714-PET/MRI, 5-year Follow-up DPA-714-PET/MRI, DPA-714 Metabolite Analysis
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 21, 2026, 7:22 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

NCT04164758
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Pimavanserin, Placebo, Quetiapine
Drug · Other
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
16
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 21, 2026, 7:22 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT

NCT04062526
View directory record Official record
Conditions
Parkinson Disease, Healthy Volunteer
Interventions
[18F]NOS
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness

NCT03194217
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Parkinson Disease
Interventions
BEN-2001, Placebo
Drug
Lead sponsor
BenevolentAI Bio
Industry
Eligibility
50 Years to 80 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 21, 2026, 7:22 AM EDT